Groupama Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Groupama Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.6M	Sell	30,941 -4,297	-12%	-$2.2M	0.21%	70
2026 Q1	$18.4M	Buy	35,238 +4,618	+15%	+$2.21M	0.27%	66
2025 Q4	$17.8M	Buy	30,620 +3,176	+12%	+$1.62M	0.26%	67
2025 Q3	$12.6M	Sell	27,444 -13,447	-33%	-$5.02M	0.18%	72
2025 Q2	$12.3M	Buy	40,891 +7,439	+22%	+$2.22M	0.2%	74
2025 Q1	$11M	Buy	33,452 +9,128	+38%	+$3M	0.22%	73
2024 Q4	$7.58M	Buy	24,324 +11,487	+89%	+$3.23M	0.15%	87
2024 Q3	$2.19M	Buy	12,837 +963	+8%	+$246K	0.06%	169
2024 Q2	$3.33M	Buy	11,874 +11,659	+5,423%	+$2.78M	0.05%	152
2024 Q1	$3.02M	Sell	215 -8,814	-98%	-$2.08M	0.06%	185
2023 Q4	$2.09M	Buy	+9,029	New	+$1.58M	0.05%	202

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Groupama Asset Management's MDGL Position: Q2 2026 in Review

Groupama Asset Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 12% in Q2 2026, selling an estimated $2.2M and leaving 30,941 shares worth $16.6M. The position accounts for 0.21% of the portfolio, ranked #70.

Groupama Asset Management first reported a position in MDGL in Q4 2023 and has held it in 11 quarters since. The position peaked at $18.4M in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Groupama Asset Management held 30,941 shares of Madrigal Pharmaceuticals worth $16.6M as of Q2 2026.
Groupama Asset Management sold 4,297 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2.2M.
Madrigal Pharmaceuticals made up 0.21% of Groupama Asset Management's portfolio in Q2 2026, its #70 holding.
Groupama Asset Management first reported a position in Madrigal Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Groupama Asset Management's Madrigal Pharmaceuticals position peaked at $18.4M in Q1 2026.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Groupama Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.